Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 6;23(9):5208. doi: 10.3390/ijms23095208

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Cell assays with anti-CD20/anti-CD59 bispecific antibodies: (a) Complement-dependent cytotoxicity assay in rituximab (RX)-(left) and HuMax-20 (HX)-(right) format on Raji cells and RX-based mAb² on ARH-77 cells (center). Sample size was n = 3 for Raji and n = 2 for ARH-77 cells. One-way ANOVA was used to determine the significance (* 0.01 ≤ p < 0.05, ** 0.001 ≤ p < 0.01, *** 0.0001 ≤ p < 0.001, **** p ≤ 0.0001); (b) SK-BR-3 cell staining of RX-BER mAb² molecules (left panel), the interaction of RX-BER2 and RX with SK-BR-3 cells with and without phospholipase C (PLC)-treatment (central panel), MEM-43-staining of SK-BR-3 cells with and without PLC treatment (right panel). 2nd only: cells stained with fluorescent conjugate only, without primary antibody. Presented are mean and S.D.

Cell assays with anti-CD20/anti-CD59 bispecific antibodies: (a) Complement-dependent cytotoxicity assay in rituximab (RX)-(left) and HuMax-20 (HX)-(right) format on Raji cells and RX-based mAb² on ARH-77 cells (center). Sample size was n = 3 for Raji and n = 2 for ARH-77 cells. One-way ANOVA was used to determine the significance (* 0.01 ≤ p < 0.05, ** 0.001 ≤ p < 0.01, *** 0.0001 ≤ p < 0.001, **** p ≤ 0.0001); (b) SK-BR-3 cell staining of RX-BER mAb² molecules (left panel), the interaction of RX-BER2 and RX with SK-BR-3 cells with and without phospholipase C (PLC)-treatment (central panel), MEM-43-staining of SK-BR-3 cells with and without PLC treatment (right panel). 2nd only: cells stained with fluorescent conjugate only, without primary antibody. Presented are mean and S.D.